Carl June’s Cancer Startup Raises $100 Million From Gilead, Sean Parker – Forbes
Forbes |
Carl June's Cancer Startup Raises $100 Million From Gilead, Sean Parker
Forbes Both attempt to use genetically modified T–cells, which have proven effective in late-stage blood cancers, against more common solid tumors, which are more difficult for the immune system to penetrate. One treatment is what is known as a chimeric … Tmunity Reels in $100M for “Next Generation” Cancer Immunotherapy |
